254 Results
Biodesix, Inc. today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021.
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11.
Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the first quarter and provided a corporate update.
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans. Read more >>
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS Cov-2 Neutralization Antibody Test (cPass™ Neutralization Test Kit, GenScript Inc.).
In this webinar, Dr. Garwood will discuss identification of malignant lung nodules in a distributed population and how risk assessment using blood-based biomarker testing can help standardize referral patterns by stratifying patients who can be safely monitored with computerized tomography (CT) surveillance and those that should be referred to a specialist for diagnostic intervention.
Biodesix, Inc. and Addario Lung Cancer Medical Institute (ALCMI) today announced they will present on the progress of “Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy (BEACON-Lung).”
Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time. Read more >>
